Journal of the Pancreas Open Access

  • ISSN: 1590-8577
  • Journal h-index: 79
  • Journal CiteScore: 29.12
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days


Neuroendocrine Tumors: Treatment Updates

Muhammad Wasif Saif, Simon Khagi

Neuroendocrine tumors of the gastroenteropancreatic tract remain a difficult array of neoplasia to treat. Treatment ofadvanced and metastatic gastroenteropancreatic neuroendocrine tumors has traditionally been difficult with few systemictreatment options. In 2011, two new targeted therapies, everolimus and sunitinib were approved for treatment of pancreaticneuroendocrine tumor. The approval of these agents led to an enhanced interest in exploring novel agents. This can beevidenced by the fact that this is the first year that ASCO assembled related abstracts under a separate title ofneuroendocrine tumor. The annual American Society of Clinical Oncology (ASCO) conference in 2013 presented fourabstracts (#4030, #4031, #4032, #4136) that shed light on new therapeutic options that help target the unique pathwaysinvolved in these neuroendocrine malignancies.